Last update 23 Nov 2024

INS-068

Overview

Basic Info

Drug Type
Biosimilar, Hormone
Synonyms
INS068
Target
Mechanism
INSR agonists(Insulin receptor agonists)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationSpecial Review Project (CN)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
CN
31 Mar 2023
Diabetes MellitusPhase 2-18 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
455
HR17031
ysmonbiuhm(ndwckcupvx) = zbfcogeibk bbnmztmaxl (dhgzvgxwla )
Positive
14 Jun 2024
ysmonbiuhm(ndwckcupvx) = wuxiffnwle bbnmztmaxl (dhgzvgxwla )
Phase 1
98
INS068 0.4 U/kg
jkawrworac(naoxfrrtzu) = Adverse events (AEs) were mostly mild, with no deaths and only one case of serious AE reported (hypoglycemia [IDeg], reported after patient withdrawal). Treatment-related AEs occurred in 17.2% of patients with INS068 and 13.3% with IDeg, with the most common (incidence ≥2%) being hyperglycemia (6.9% vs 2.2%), injection site pain (3.4% vs 4.4%) and headache (3.4% vs 4.4%). Hypoglycemic episodes were reported in 85.1% of patients with INS068 vs 86.7% with IDeg. iyiydsmyzk (kwlogzwhnh )
Positive
30 Sep 2021
INS068 0.6 U/kg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free